NGI-1(Synonyms: ML414)

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

NGI-1 (Synonyms: ML414) 纯度: 99.90%

NGI-1 (ML414) 是一种有效的寡糖基转移酶 (OST) 抑制剂,直接靶向和阻断 OST 催化亚基 STT3A 和 STT3B 的功能。NGI-1 是一种细胞渗透性抑制剂,可有效降低病毒感染性而不影响细胞活力。

NGI-1(Synonyms: ML414)

NGI-1 Chemical Structure

CAS No. : 790702-57-7

规格 价格 是否有货 数量
Free Sample (0.1-0.5 mg)   Apply now  
10 mM * 1 mL in DMSO ¥1210 In-stock
5 mg ¥1100 In-stock
10 mg ¥1600 In-stock
50 mg ¥4900 In-stock
100 mg ¥8900 In-stock
200 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

NGI-1 相关产品

相关化合物库:

  • Bioactive Compound Library Plus
  • Anti-Infection Compound Library
  • Anti-Cancer Compound Library
  • Antiviral Compound Library
  • Peptidomimetic Library

生物活性

NGI-1 (ML414) is a potent oligosaccharyltransferase (OST) inhibitor, directly targeting and blocking the function of the OST catalytic subunits STT3A and STT3B[1]. NGI-1 is a cell permeable inhibitor and can effectively reduce virus infectivity without affecting cell viability[2].

IC50 & Target

OST[1]

体外研究
(In Vitro)

NGI-1 inhibits the glycosylation of LASV GP mediated by STT3A-OST (in STT3B- and MAGT1-TUSC3- cells) or STT3B-OST (in STT3A- cells) and impaires its proteolytic cleavage in a dose-dependent manner[1].
NGI-1 blocks EGFR N-linked glycosylation in lung adenocarcinoma cells as assessed. In controls EGFR is biotinylated, consistent with its plasma membrane expression, but in NGI-1 treated cells the EGFR is predominantly found in the non-biotinylated intracellular fraction suggesting a change in cellular localization[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis[1]

Cell Line: STT3A-, STT3B- and MAGT1-TUSC3- cells
Concentration: 1, 2, 5 μM
Incubation Time: 36 hours
Result: Inhibited the glycosylation of LASV GP mediated by STT3A-OST (in STT3B- and MAGT1-TUSC3- cells) or STT3B-OST (in STT3A- cells) and impaired its proteolytic cleavage in a dose-dependent manner.

分子量

394.51

Formula

C17H22N4O3S2

CAS 号

790702-57-7

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : 100 mg/mL (253.48 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.5348 mL 12.6740 mL 25.3479 mL
5 mM 0.5070 mL 2.5348 mL 5.0696 mL
10 mM 0.2535 mL 1.2674 mL 2.5348 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.5 mg/mL (6.34 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (6.34 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH₂O 中,得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂: 10% DMSO    90% corn oil

    Solubility: ≥ 2.5 mg/mL (6.34 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (6.34 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献
  • [1]. Zhu S, et al. Comprehensive Interactome Analysis Reveals that STT3B is Required for the N-Glycosylation of Lassa Virus Glycoprotein. J Virol. 2019 Sep 11. pii: JVI.01443-19.

    [2]. Lopez-Sambrooks C, et al. Oligosaccharyltransferase inhibition induces senescence in RTK-driven tumor cells. Nat Chem Biol. 2016 Dec;12(12):1023-1030.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务